Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and estimat ...

Organon (OGN) ended the recent trading session at $10.19, demonstrating a +1.49% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.94%. Elsewhere, the Dow saw an upswing of 0.75%, while the tech-heavy Nasdaq appreciated by 1.52%. The pharmaceutical company's stock has climbed by 11.06% in the past month, exceeding the Medical sector's gain of 4.95% and the S&P 500's gain of 1.67%.The investment community will be closely monitoring the performance o ...

诉讼背景 - 领先证券律师事务所Bleichmar Fonti & Auld LLP对Organon & Co (NYSE: OGN)及其部分高管提起集体诉讼 指控其涉嫌违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)和20(a)条款 案件由美国新泽西地区法院受理 案号Hauser v Organon & Co et al No 25-cv-05322 [2] 指控核心内容 - Organon在2024年10月完成12亿美元收购皮肤科生物制药公司Dermavant后 虽增加债务但向投资者保证维持股息政策 并称其为"第一资本配置优先事项" [3] - 实际上公司将资本配置优先级转向债务削减 最终于2025年5月1日将每股股息从028美元大幅削减至002美元 [4] 市场反应 - 股息削减公告导致股价单日暴跌27% 从2025年4月30日的1293美元/股跌至5月1日的945美元/股 [4] - 公司CEO解释称调整资本配置优先级是为加速去杠杆化 CFO明确表示"向股东返还资本目前非优先事项" [4] 公司业务背景 - Organon为全球女性健康领域医疗保健公司 历史上以稳定股息回报股东 [3] - Dermavant收购使其债务水平显著上升 但管理层最初向市场传递维持股息的误导性信息 [3][4] 律所背景 - 原告律所Bleichmar Fonti & Auld LLP在证券集体诉讼领域具有领先地位 2023年被ISS SCAS评为全美前五大原告律所 [6] - 该律所近期成功案例包括从特斯拉董事会追回9亿美元赔偿 以及从Teva制药获42亿美元和解 [7]

NEW YORK, June 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=152953&from=4CLASS PERIOD: October 31, 2024 to April 30, 20 ...

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...

LOS ANGELES, June 13, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 22, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Organon & Co. (“Organon” or the “Company”) (NYSE: OGN) securities between October 31, 2024 to April 30, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR ORGANON INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YO ...

集体诉讼案件 - Organon公司因违反联邦证券法面临集体诉讼，涉及2024年10月31日至2025年4月30日期间购买公司证券的股东 [1] - 诉讼指控公司关于资本分配优先事项的声明存在虚假和误导性，特别是季度股息支付前景 [2] - 公司宣称股息为"首要任务"，但实际执行债务削减策略导致股息减少70% [2] 法律事务细节 - 诉讼核心矛盾在于公司公开承诺与实际行动不符，股息优先级与债务削减策略直接冲突 [2] - 受影响股东需在2025年7月22日前联系DJS Law Group参与诉讼 [1] 律师事务所背景 - DJS Law Group专注于通过证券集体诉讼和公司治理诉讼提升投资者回报 [3] - 客户群体包括全球顶级对冲基金和另类资产管理公司 [3] - 业务范围涵盖国内外并购评估等复杂金融法律事务 [3]

NEW YORK, June 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid ...

法律调查与投资者诉讼 - 律师事务所Faruqi & Faruqi正在调查Organon & Co潜在证券索赔案件 并提醒投资者在2025年7月22日前申请成为集体诉讼的首席原告 [3] - 调查涉及Organon在2024年10月31日至2025年4月30日期间可能存在的证券欺诈行为 鼓励受影响投资者联系律所 [1][3] - 律所在证券诉讼领域有丰富经验 自1995年成立以来已为投资者追回数亿美元损失 [4] 公司信息披露问题 - Organon管理层被指控在资本分配策略上发布误导性声明 强调季度分红是"第一优先级" 但隐瞒了债务削减计划的实际优先级 [5] - 公司收购Dermavant后 季度分红骤降70% 但未及时披露债务重组对分红政策的实质性影响 [5] - 这些信息缺失导致投资者以虚高价格买入公司证券 [5] 市场反应 - 2025年4月30日至5月1日期间 Organon股价从每股12 93美元暴跌至9 45美元 单日跌幅超过27% [6] - 股价剧烈波动直接源于公司资本分配策略真相的披露 [5][6] 诉讼程序 - 法院将指定财务利益最大的适格投资者作为首席原告 代表集体诉讼成员主导诉讼进程 [7] - 投资者可选择主动担任首席原告或保持缺席成员身份 均不影响最终赔偿权益 [8] - 律所同时征集知情人士提供线索 包括举报人、前员工和股东等 [8]